Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.21 +3.2%	$13.17	$8.04 ▼ $25.88	$320.84M	2.26	387,948 shs	412,423 shs
AURA Aura Biosciences	$6.84 +3.2%	$6.52	$4.34 ▼ $12.38	$333.28M	0.46	166,091 shs	140,010 shs
IVVD Invivyd	$0.72 -1.0%	$0.78	$0.35 ▼ $2.74	$86.86M	0.51	680,336 shs	536,813 shs
KOD Kodiak Sciences	$8.21 +1.5%	$4.87	$1.92 ▼ $11.60	$426.86M	2.41	658,986 shs	482,041 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+3.21%	-3.63%	-8.61%	+7.29%	-38.43%
AURA Aura Biosciences	+3.17%	+3.79%	+11.04%	+17.93%	-22.54%
IVVD Invivyd	-0.98%	-4.64%	+1.90%	+23.20%	-33.61%
KOD Kodiak Sciences	+1.48%	+12.47%	+121.29%	+104.99%	+228.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.8118 of 5 stars	3.6	2.0	0.0	2.8	2.5	0.6
AURA Aura Biosciences	2.1003 of 5 stars	3.6	0.0	0.0	2.6	3.3	0.0
IVVD Invivyd	3.0223 of 5 stars	3.6	4.0	0.0	0.6	3.3	0.6
KOD Kodiak Sciences	2.418 of 5 stars	1.0	1.0	4.6	2.7	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	342.26% Upside
AURA Aura Biosciences	3.25	Buy	$22.00	221.64% Upside
IVVD Invivyd	3.25	Buy	$5.85	715.90% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	9.62% Upside

Current Analyst Ratings Breakdown

Latest IVVD, KOD, AURA, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/28/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/16/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	2.17	N/A	N/A	$8.90 per share	1.37
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
IVVD Invivyd	$25.38M	3.39	N/A	N/A	$0.56 per share	1.28
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/11/2025 (Estimated)
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
IVVD Invivyd	-$169.93M	-$1.20	N/A	6.52	N/A	-389.01%	-165.24%	-99.71%	8/13/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)

Latest IVVD, KOD, AURA, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AURA Aura Biosciences	-$0.47	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	IVVD Invivyd	-$0.04	N/A	N/A	N/A	$23.16 million	N/A
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	N/A	N/A	N/A	$17.64 million	N/A
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/15/2025	Q1 2025	IVVD Invivyd	-$0.04	-$0.14	-$0.10	-$0.14	$34.45 million	$11.30 million
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
AURA Aura Biosciences	N/A	11.06	11.06
IVVD Invivyd	N/A	1.53	1.53
KOD Kodiak Sciences	N/A	4.62	4.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
AURA Aura Biosciences	96.75%
IVVD Invivyd	70.36%
KOD Kodiak Sciences	89.06%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
AURA Aura Biosciences	5.40%
IVVD Invivyd	25.40%
KOD Kodiak Sciences	45.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
IVVD Invivyd	100	119.96 million	89.49 million	Optionable
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable

IVVD, KOD, AURA, and ARCT Headlines

Recent News About These Companies

Kodiak Sciences (KOD) to Release Earnings on Wednesday

August 6 at 4:54 AM | marketbeat.com

Kodiak Sciences Inc. (NASDAQ:KOD) Shares Bought by GSA Capital Partners LLP

August 4 at 3:40 AM | marketbeat.com

Kodiak Sciences Inc. (KOD) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Tsunami alerts for Alaska canceled after 7.3-magnitude earthquake off Aleutians

July 18, 2025 | msn.com

Part 1: Johnson recounts PTSD treatment after May breakdown

July 17, 2025 | kodiakdailymirror.comK

Enduring the heat of California

July 15, 2025 | kodiakdailymirror.comK

Penny Stocks To Watch In July 2025

July 11, 2025 | finance.yahoo.com

NASDAQ:KOD Financials | Kodiak Sciences Inc - Investing.com

July 10, 2025 | investing.com

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

July 10, 2025 | prnewswire.com

Peapod Lane Capital LLC Trims Position in Kodiak Sciences Inc. (NASDAQ:KOD)

July 10, 2025 | marketbeat.com

Kodiak Sciences (NASDAQ:KOD) Stock Price Up 5.1% - Time to Buy?

July 9, 2025 | marketbeat.com

Kodiak Sciences Inc. Advanced Charts | KOD | Barron's

July 9, 2025 | barrons.com

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society - Morningstar

June 27, 2025 | morningstar.comM

Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)

June 27, 2025 | ophthalmologytimes.comO

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

June 25, 2025 | prnewswire.com

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

June 13, 2025 | zacks.com

Trump’s cuts to fisheries science have industry and conservation groups sounding alarm

June 11, 2025 | kucb.orgK

Alaska Aerospace, UAF to partner on new space ventures

June 11, 2025 | kodiakdailymirror.comK

Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

June 5, 2025 | theglobeandmail.com

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025 | prnewswire.com

Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads

May 29, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]
By MarketBeat Staff | July 29, 2025
View Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]
3 Fast Food Stocks That Won’t Give You Indigestion Right Now
By Brian O'Connell | July 16, 2025
View 3 Fast Food Stocks That Won’t Give You Indigestion Right Now
How Texas Roadhouse Is Winning in a Changing Consumer Market
By Dan Schmidt | July 14, 2025
View How Texas Roadhouse Is Winning in a Changing Consumer Market

IVVD, KOD, AURA, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$12.21 +0.38 (+3.21%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$20.50 +8.29 (+67.90%)

As of 04:00 AM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Aura Biosciences NASDAQ:AURA

$6.84 +0.21 (+3.17%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$7.12 +0.28 (+4.08%)

As of 04:04 AM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Invivyd NASDAQ:IVVD

$0.72 -0.01 (-0.98%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$0.74 +0.02 (+2.65%)

As of 04:04 AM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Kodiak Sciences NASDAQ:KOD

$8.21 +0.12 (+1.48%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$4.50 -3.71 (-45.19%)

As of 04:00 AM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time